Effect Evaluation of Melatonin in treatment of Polycystic Ovarian Syndrome

Phase 2

• Conditions: E28.2; Polycystic ovarian syndrome.; Polycystic ovarian syndrome

• Registration Number: IRCT20200711048078N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 88

Inclusion Criteria

Women in reproductive age (18-45)
Women diagnosed with PCOS, based on Rotterdam criteria
Who doesn't want to get pregnant for at least 3 months
Most of patients are new cases
If the patient has a medical history of taking medicines, should discontinue medications for at least 3 months before entering the study

Exclusion Criteria

Breastfeeding
Wants to get pregnant
Adrenal Hyperplasia
Hyper Prolactinemia
Mental Disorders
Hypothyroidism
Patients using hormonal medications or medications that cause weight loss and weight gain
who's on a diet

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
H (luteinizing hormone) to FSH (follicle stimulating hormone) ratio. Timepoint: Measurement of blood LH and FSH levels at the beginning and end of the study. Method of measurement: Blood test.;BMI (body mass index). Timepoint: Measurement of height and weight at the beginning and end of the study. Method of measurement: Scale and stadiometer.;Quality of life. Timepoint: At the beginning and end of the study. Method of measurement: PCOSQ (polycystic ovarian syndrome quality of life questionnaire).;Hirsutism. Timepoint: At the beginning and end of the study. Method of measurement: Ferriman-Gallwey scoring scale.